Operating
Change in AP
Neurocrine Biosciences Change in AP decreased by 118.7% to -$14.30M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 376.7%, from -$3.00M to -$14.30M. Over 3 years (FY 2021 to FY 2025), Change in AP shows an upward trend with a 41.3% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
StatementCash Flow Statement
SectionOperating
CategoryLiquidity
SignalHigher is better
VolatilityModerate
First reportedQ1 2013
Last reportedQ1 2026May 5, 2026
How to read this metric
An increase is generally positive for cash flow, as it allows the company to retain cash longer, provided it does not damage supplier relationships.
Detailed definition
This measures the change in the amount the company owes to its suppliers and vendors for goods and services received. An...
Peer comparison
Standard metric; companies often aim to optimize payment terms to maximize cash availability.
Metric ID:
change_in_accounts_payableHistorical Data
19 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $18.00M | $8.70M | $19.10M | $11.50M | $32.70M | $32.80M | $37.60M | $6.70M | $16.20M | $124.40M | -$18.60M | -$59.50M | $44.20M | $77.30M | -$3.00M | $30.90M | $55.80M | $76.50M | -$14.30M |
| QoQ Change | — | -51.7% | +119.5% | -39.8% | +184.3% | +0.3% | +14.6% | -82.2% | +141.8% | +667.9% | -115.0% | -219.9% | +174.3% | +74.9% | -103.9% | >999% | +80.6% | +37.1% | -118.7% |
| YoY Change | — | — | — | — | +81.7% | +277.0% | +96.9% | -41.7% | -50.5% | +279.3% | -377.6% | -467.3% | -64.5% | — | +83.9% | +151.9% | +26.2% | -1.0% | -376.7% |
Range-$59.50M – $124.40M
CAGR-5.0%
Avg YoY Growth-27.3%
Median YoY Growth+12.6%
Change in AP at Other Companies
Frequently Asked Questions
- What is Neurocrine Biosciences's change in ap?
- Neurocrine Biosciences (NBIX) reported change in ap of -$14.30M in Q1 2026.
- How has Neurocrine Biosciences's change in ap changed year-over-year?
- Neurocrine Biosciences's change in ap decreased by 376.7% year-over-year, from -$3.00M to -$14.30M.
- What is the long-term trend for Neurocrine Biosciences's change in ap?
- Over 3 years (2021 to 2025), Neurocrine Biosciences's change in ap has grown at a 41.3% compound annual growth rate (CAGR), from $56.80M to $160.20M.
- What does change in ap mean?
- The change in money the company owes to its suppliers.